Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy

被引:0
|
作者
Mark J. Alberts
Jinghua He
Akshay Kharat
Veronica Ashton
机构
[1] Hartford HealthCare,
[2] Janssen Scientific Affairs,undefined
[3] LLC,undefined
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:425 / 436
页数:11
相关论文
共 50 条
  • [1] Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
    Alberts, Mark J.
    He, Jinghua
    Kharat, Akshay
    Ashton, Veronica
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2022, 22 (04) : 425 - 436
  • [2] Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
    Martinez, Brandon K.
    Baker, William L.
    Sood, Nitesh A.
    Bunz, Thomas J.
    Meinecke, Anna-Katharina
    Eriksson, Daniel
    Coleman, Craig, I
    [J]. PHARMACOTHERAPY, 2019, 39 (02): : 196 - 203
  • [3] Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
    Coleman, Craig, I
    Martinez, Brandon K.
    Bunz, Thomas J.
    Eriksson, Daniel
    Meinecke, Anna-Katharina
    Sood, Nitesh
    Baker, William L.
    [J]. CIRCULATION, 2018, 138
  • [4] Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes
    Weir, Matthew R.
    Chen, Yen-Wen
    He, Jinghua
    Bookhart, Brahim
    Campbell, Alicia
    Ashton, Veronica
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (11)
  • [5] Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy
    Laliberte, Francois
    Ashton, Veronica
    Kharat, Akshay
    Lejeune, Dominique
    Moore, Kenneth Todd
    Jung, Young
    Lefebvre, Patrick
    Berger, Jeffrey S.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (16) : 1235 - 1250
  • [6] Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)
    Berger, Jeffrey S.
    Laliberte, Francois
    Kharat, Akshay
    Lejeune, Dominique
    Moore, Kenneth Todd
    Jung, Young
    Lefebvre, Patrick
    Ashton, Veronica
    [J]. ADVANCES IN THERAPY, 2021, 38 (07) : 3771 - 3788
  • [7] Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)
    Jeffrey S. Berger
    François Laliberté
    Akshay Kharat
    Dominique Lejeune
    Kenneth Todd Moore
    Young Jung
    Patrick Lefebvre
    Veronica Ashton
    [J]. Advances in Therapy, 2021, 38 : 3771 - 3788
  • [8] Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation
    Piccini, Jonathan P.
    Hellkamp, Anne S.
    Washam, Jeffrey B.
    Becker, Richard C.
    Breithardt, Guenter
    Berkowitz, Scott D.
    Halperin, Jonathan L.
    Hankey, Graeme J.
    Hacke, Werner
    Mahaffey, Kenneth W.
    Nessel, Christopher C.
    Singer, Daniel E.
    Fox, Keith A. A.
    Patel, Manesh R.
    [J]. CIRCULATION, 2016, 133 (04) : 352 - 360
  • [9] Effectiveness and safety of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and heart failure
    Coleman, C. I.
    Baker, W. L.
    Bunz, T. J.
    Eriksson, D.
    Meinecke, A. K.
    Sood, N. A.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 : 1012 - 1012
  • [10] Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
    Yao, Xiaoxi
    Abraham, Neena S.
    Sangaralingham, Lindsey R.
    Bellolio, M. Fernanda
    McBane, Robert D.
    Shah, Nilay D.
    Noseworthy, Peter A.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (06):